Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors

Hematological Oncology

Volumn 30, Issue 1, 2012, Pages 27-33

  Tibullo, Daniele ^a   Barbagallo, Ignazio ^a   Giallongo, Cesarina ^a   La Cava, Piera ^a   Branca, Antonio ^a   Conticello, Concetta ^b   Stagno, Fabio ^a   Chiarenza, Annalisa ^a   Palumbo, Giuseppe A ^a   Raimondo, Francesco Di ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Mediterranean Institute of Oncology   (Italy)

Author keywords

Bosutinib; Chronic myeloid leukemia; Dasatinib; Nilotinib; Osteogenic differentiation

Indexed keywords

BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 2; BOSUTINIB; DASATINIB; MESSENGER RNA; NILOTINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; BINDING AFFINITY; BONE DEVELOPMENT; BONE MARROW; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MESENCHYME CELL; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING;

BONE MORPHOGENETIC PROTEIN 2; CELL DIFFERENTIATION; HUMANS; MESENCHYMAL STEM CELLS; NF-KAPPA B; OSTEOBLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RANK LIGAND; TISSUE DONORS;

EID: 84858149169     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.988     Document Type: Article

References (37)

1. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5(3): 172-183.
2. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354(19): 2006-2013.
3. Joensuu H, Reichardt P. Imatinib and altered bone and mineral metabolism. N Engl J Med 2006; 355(6): 628-629.
4. Owen S, Hatfield A, Letvak L. Imatinib and altered bone and mineral metabolism. N Engl J Med 2006; 355(6): 8-9.
5. Tournis S, Lyritis GP. Imatinib and altered bone and mineral metabolism. N Engl J Med 2006; 355(6): 8-9.
6. Fitter S, Dewar AL, Kostakis P, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008; 111(5): 2538-2547.
7. Jonsson S, Olsson B, Ohlsson C, Lorentzon M, Mellstrom D, Wadenvik H. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica 2008; 93(7): 1101-1103.
8. O'Sullivan S, Horne A, Wattie D, et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 2009; 94(4): 1131-1136.
9. Tibullo D, Giallongo C, La Cava P, et al. Effects of imatinib mesylate in osteoblastogenesis. Exp Hematol 2009; 37(4): 461-468.
10. Fierro F, Illmer T, Jing D, et al. Inhibition of platelet-derived growth factor receptor beta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Prolif 2007; 40(3): 355-366.
11. O'Sullivan S, Naot D, Callon K, et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 2007; 22(11): 1679-1689.
12. Wihlidal P, Karlic H, Pfeilstocker M, Klaushofer K, Varga F. Imatinib mesylate (IM)-induced growth inhibition is associated with production of spliced osteocalcin-mRNA in cell lines. Leuk Res 2008; 32(3): 437-443.
13. Tokunaga A, Oya T, Ishii Y, et al. PDGF receptor beta is a potent regulator of mesenchymal stromal cell function. J Bone Miner Res 2008; 23(9): 1519-1528.
14. Dewar AL, Farrugia AN, Condina MR, et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood 2006; 107(11): 4334-4337.
15. Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 2001; 19(3):180-92.
16. Barbagallo I, Tibullo D, Di Rosa M, et al. A cytoprotective role for the heme oxygenase-1/CO pathway during neural differentiation of human mesenchymal stem cells. J Neurosci Res 2008; 86(9): 1927-1935.
17. Bernardo ME, Locatelli F, Fibbe WE. Mesenchymal stromal cells. Ann N Y Acad Sci 2009; 1176: 101-117.
18. Bernardo A, Bianchi D, Magnaghi V, Minghetti L. Peroxisome proliferator-activated receptor-gamma agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells. J Neuropathol Exp Neurol 2009; 68(7): 797-808.
19. Chau JF, Leong WF, Li B. Signaling pathways governing osteoblast proliferation, differentiation and function. Histol Histopathol 2009; 24(12): 1593-1606.
20. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+neoplastic cells. Cancer Res 2006; 66(23): 11314-11322.
21. Johnson FM, Agrawal S, Burris H, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010; 116(6): 1582-1591.
22. Tanaka C, Yin OQ, Sethuraman V, et al. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 2010; 87(2): 197-203.
23. Snead JL, O'Hare T, Adrian LT, et al. Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood 2009; 114(16): 3459-3463.
24. Vandyke K, Dewar AL, Diamond P, et al. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J Bone Miner Res 2010; 25(8): 1759-1770.
25. Id Boufker H, Lagneaux L, Najar M, et al. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer 2010; 10: 298.
26. Jonsson S, Hjorth-Hansen H, Olsson B, Wadenvik H, Sundan A, Standal T. Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro. Leukemia; 24(7): 1357-1359.
27. Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res 2008; 68(23): 9624-9633.
28. Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2008; 111(4): 2329-2338.
29. Javed A, Bae JS, Afzal F, et al. Structural coupling of Smad and Runx2 for execution of the BMP2 osteogenic signal. J Biol Chem 2008; 283(13): 8412-8422.
30. Fiedler J, Roderer G, Gunther KP, Brenner RE. BMP-2, BMP-4, and PDGF-bb stimulate chemotactic migration of primary human mesenchymal progenitor cells. J Cell Biochem 2002; 87(3): 305-312.
31. Ryoo HM, Lee MH, Kim YJ. Critical molecular switches involved in BMP-2-induced osteogenic differentiation of mesenchymal cells. Gene 2006; 366(1): 51-57.
32. Ryoo HM, Wang XP. Control of tooth morphogenesis by Runx2. Crit Rev Eukaryot Gene Expr 2006; 16(2): 143-154.
33. Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 1997; 389(6651): 618-622.
34. Aubin J, Davy A, Soriano P. In vivo convergence of BMP and MAPK signaling pathways: impact of differential Smad1 phosphorylation on development and homeostasis. Genes Dev 2004; 18(12): 1482-1494.
35. Vandyke K, Dewar AL, Farrugia AN, et al. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2009; 23(5): 994-997.
36. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28(5): 524-531.
37. Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. Int J Hematol 2009; 89(2): 251-252.